医药制造业上市公司创新能力与绩效关系的实证研究

发布时间：2019-02-24 18:19

【摘要】：医药制造业是涉及国民健康、社会稳定和经济发展的重要产业，也是世界上发展最快、竞争最为激烈的产业之一。随着经济开放化进程的加快，如何有效提升医药制造业企业创新能力，提高企业绩效，保持企业持续发展，这无疑是当今企业急需关注和解决的重要问题。研究医药制造业企业创新能力与绩效的关系，不仅对企业发展具有指导意义，而且对政府制定相关政策具有参考作用。本文采用理论与实证相结合的分析方法，首先根据国内外关于企业创新能力与绩效的相关文献及理论知识，界定了企业创新能力内涵及医药制造业企业创新能力的构成要素，阐述了医药制造业企业创新能力构成要素即市场营销创新能力、管理创新能力、技术创新能力、制度创新能力这四要素的内在关系及各要素对企业绩效的作用机理；其次，基于医药制造业发展状况及行业特征，选取上交所36家医药制造业样本企业，构建了医药制造业上市公司创新能力评价指标体系。并采用因子分析法分析得到医药制造业上市公司创新能力整体水平不高，企业之间创新能力差距较大，，应加强创新能力的培育这一结论；再次，运用主营业务利润率来衡量企业绩效，提出假设并建立回归模型，得出医药制造业上市公司创新能力与企业绩效呈正相关，企业创新能力四大要素对企业绩效产生正面的影响。同时反映医药制造业上市公司创新能力的10大指标中四大指标（技术人员投入率、全员劳动生产率、国有股占比、销售人员投入率）与企业绩效关系为负，表明医药制造业上市公司更应注重这四个方面的投入；最后，依据理论及实证研究，对提升医药制造业企业创新能力提出了针对性的建议。
[Abstract]:Pharmaceutical manufacturing industry is an important industry involving national health, social stability and economic development. It is also one of the fastest growing and most competitive industries in the world. With the acceleration of the process of economic opening, how to effectively improve the innovation ability of pharmaceutical manufacturing enterprises, improve the performance of enterprises, and maintain the sustainable development of enterprises, this is undoubtedly an important issue that enterprises need to pay close attention to and solve. The study of the relationship between innovation ability and performance of pharmaceutical manufacturing enterprises is not only of guiding significance to the development of enterprises, but also of reference to the government in formulating relevant policies. This article uses the theory and the demonstration to combine the analysis method, first according to the domestic and foreign related literature and the theory knowledge about the enterprise innovation ability and the performance, has defined the enterprise innovation ability connotation and the medicine manufacturing enterprise innovation ability constituent factor. This paper expounds the internal relations of the four elements of pharmaceutical manufacturing enterprises' innovation ability, that is, marketing innovation ability, management innovation ability, technological innovation ability and institutional innovation ability, and the mechanism of each factor acting on the enterprise performance. Secondly, based on the development situation and industry characteristics of pharmaceutical manufacturing industry, 36 pharmaceutical manufacturing sample enterprises are selected from Shanghai Stock Exchange, and the evaluation index system of innovation ability of listed pharmaceutical manufacturing companies is constructed. The conclusion is that the overall level of innovation ability of listed pharmaceutical manufacturing companies is not high, and the gap between enterprises is large, so we should strengthen the cultivation of innovation ability. Thirdly, the main business profit margin is used to measure the performance of the company, and the hypothesis is put forward and the regression model is established. The conclusion is that the innovation ability of the listed pharmaceutical manufacturing company is positively correlated with the enterprise performance. The four elements of enterprise innovation ability have a positive effect on enterprise performance. At the same time, four of the 10 indexes reflecting the innovation ability of listed companies in pharmaceutical manufacturing industry (technical personnel input rate, total labor productivity, proportion of state-owned shares, investment rate of sales personnel) have negative relationship with enterprise performance. It shows that the listed companies in the pharmaceutical manufacturing industry should pay more attention to the investment in these four aspects; Finally, based on the theoretical and empirical research, some suggestions are put forward to improve the innovation ability of pharmaceutical manufacturing enterprises.
【学位授予单位】：重庆工商大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：F426.72;F273.1

【参考文献】